Crossover versus parallel designs: dose-escalation design comparisons for first-in-human studies
Related Experiment Video
Updated: May 10, 2026

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
Zhiwu Yan1, Balakrishna Hosmane, Charles Locke
1Allergan, Inc., Irvine, CA 92612, USA. yan_zhiwu@allergan.com
Abstract:
We study the statistical efficiency for rising-dose designs in the context of first-in-human studies. Specifically, we identify a class of crossover designs that are appealing in terms of both subject safety and statistical efficiency and, for a three-period, two-panel design in such a class, we compare its A-efficiency relative to the corresponding parallel designs and optimal/efficient crossover designs, respectively, under various plausible models. In the meantime, we also evaluate the impact of inclusion of baseline measurements as a covariate in the statistical analysis, for both crossover and parallel studies.
More Related Videos
Related Concept Videos
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Dosage Regimens: Designs and Approaches
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioavailability Study Design: Healthy Subjects Versus Patients

